Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis following newborn screening.
暂无分享,去创建一个
C. Whitchurch | L. Turnbull | C. Wainwright | K. Grimwood | S. Anuj | C. Harmer | J. Manos | B. Rose | C. Harbour | J. Cheney | H. Hu | I. Zablotska
[1] J. Carlin,et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. , 2011, JAMA.
[2] P. Mogayzel,et al. Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. , 2010, Paediatric respiratory reviews.
[3] J. Lipuma. The Changing Microbial Epidemiology in Cystic Fibrosis , 2010, Clinical Microbiology Reviews.
[4] D. Hassett,et al. Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies , 2010, Expert opinion on therapeutic targets.
[5] A. Hauser. The type III secretion system of Pseudomonas aeruginosa: infection by injection , 2009, Nature Reviews Microbiology.
[6] M. Elkins,et al. Low Rates of Pseudomonas aeruginosa Misidentification in Isolates from Cystic Fibrosis Patients , 2009, Journal of Clinical Microbiology.
[7] J. Engel,et al. Role of Pseudomonas aeruginosa type III effectors in disease. , 2009, Current opinion in microbiology.
[8] S. Bell,et al. Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. , 2009, Diagnostic microbiology and infectious disease.
[9] S. McColley,et al. Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection. , 2008, Translational research : the journal of laboratory and clinical medicine.
[10] N. Høiby,et al. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[11] D. Wareham,et al. A genotypic and phenotypic comparison of type III secretion profiles of Pseudomonas aeruginosa cystic fibrosis and bacteremia isolates. , 2007, International journal of medical microbiology : IJMM.
[12] R. Koski,et al. Annals of Clinical Microbiology and Antimicrobials Open Access an Indirect Enzyme-linked Immunosorbent Assay for Rapid and Quantitative Assessment of Type Iii Virulence Phenotypes of Pseudomonas Aeruginosa Isolates , 2005 .
[13] J. Carlin,et al. Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic. , 2005, American journal of respiratory and critical care medicine.
[14] Vincent T. Lee,et al. Activities of Pseudomonas aeruginosa Effectors Secreted by the Type III Secretion System In Vitro and during Infection , 2005, Infection and Immunity.
[15] A. Hauser,et al. Relative Contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to Virulence in the Lung , 2004, Infection and Immunity.
[16] S. McColley,et al. Type III Secretion Phenotypes of Pseudomonas aeruginosa Strains Change during Infection of Individuals with Cystic Fibrosis , 2004, Journal of Clinical Microbiology.
[17] S. Bell,et al. Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units , 2004, European Respiratory Journal.
[18] P. Molina,et al. High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. , 2004, The Journal of pediatrics.
[19] J. Rello,et al. Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. , 2003, The Journal of infectious diseases.
[20] J. Wiener-Kronish,et al. Single-Nucleotide-Polymorphism Mapping of the Pseudomonas aeruginosa Type III Secretion Toxins for Development of a Diagnostic Multiplex PCR System , 2003, Journal of Clinical Microbiology.
[21] M. Elkins,et al. Genetic Analysis of Pseudomonas aeruginosa Isolates from the Sputa of Australian Adult Cystic Fibrosis Patients , 2002, Journal of Clinical Microbiology.
[22] A. Hauser,et al. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. , 2001, Microbiology.
[23] R. Savel,et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. , 2001, The Journal of infectious diseases.
[24] J. Emerson,et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. , 2001, The Journal of infectious diseases.
[25] S. Lory,et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.
[26] F. Ausubel,et al. Pseudomonas aeruginosa killing of Caenorhabditis elegans used to identify P. aeruginosa virulence factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[27] D H Persing,et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.
[28] D. Woods,et al. Elevated exoenzyme expression by Pseudomonas aeruginosa is correlated with exacerbations of lung disease in cystic fibrosis. , 1993, Pediatric pulmonology.